2014
DOI: 10.1371/journal.pone.0085336
|View full text |Cite
|
Sign up to set email alerts
|

Tumorigenicity Studies of Induced Pluripotent Stem Cell (iPSC)-Derived Retinal Pigment Epithelium (RPE) for the Treatment of Age-Related Macular Degeneration

Abstract: Basic studies of human pluripotential stem cells have advanced rapidly and stem cell products are now seeing therapeutic applications. However, questions remain regarding the tumorigenic potential of such cells. Here, we report the tumorigenic potential of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of wet-type, age-related macular degeneration (AMD). First, immunodeficient mouse strains (nude, SCID, NOD-SCID and NOG) were tested for HeLa cells’ tumor-forming… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
122
0

Year Published

2015
2015
2020
2020

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 157 publications
(122 citation statements)
references
References 18 publications
0
122
0
Order By: Relevance
“…Prior to commencing the 1st ever human clinical trial with iPSC, rigorous safety trials (in mouse and monkeys) took place to validate application of retinal epithelial sheets without subsequent tumorigenesis [124,125]. The swift journey from skin to eyes started in September 2014, when ophthalmologist Masayo Takahashi collaborated with the stem cell pioneer Shinya Yamanaka and transplanted RPE (retinal pigment epithelium) sheets generated from patients iPS cells into the right eye of the female suffering from age related macular degeneration.…”
Section: Discussionmentioning
confidence: 99%
“…Prior to commencing the 1st ever human clinical trial with iPSC, rigorous safety trials (in mouse and monkeys) took place to validate application of retinal epithelial sheets without subsequent tumorigenesis [124,125]. The swift journey from skin to eyes started in September 2014, when ophthalmologist Masayo Takahashi collaborated with the stem cell pioneer Shinya Yamanaka and transplanted RPE (retinal pigment epithelium) sheets generated from patients iPS cells into the right eye of the female suffering from age related macular degeneration.…”
Section: Discussionmentioning
confidence: 99%
“…In the ISCBI survey (see Appendix 9) seven different strains of immunedeficient mice were reported in use, some of which retain certain immune cell functions. For tumorigenicity testing mouse strains with multiple immune deficiencies, including lack of functional T-and B-lymphocytes and NK cells are recommended, including NOG (NOD/Shiscid/IL2Rgnull) [60,61] and also the NGS [263]. In addition, the time period of observation of inoculated animal and its predisposition to develop spontaneous tumors may also affect results of future science group Supplement International Stem Cell Banking Initiative (ISCBI) tumorigenicity assays.…”
Section: Tumorigenicity Testingmentioning
confidence: 99%
“…Insulin-producing cells have then been produced in vitro from iPSCs by directed differentiation, using small molecules and growth factors in culture (Raikwar et al, 2015). The advantage of using iPSCs is the absence of ethical concerns, and low risk of teratoma formation (Kanemura et al, 2014).…”
Section: Induced Pluripotent Stem Cellsmentioning
confidence: 99%